Takeda announces positive results from two pivotal phase 3 studies of oveporexton (tak-861) in narcolepsy type 1

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that all primary and secondary endpoints were met in two phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (tak-861), a potential first-in-class investigational oral orexin receptor 2 (ox2r)-selective agonist, in narcolepsy type 1 (nt1). nt1 is caused by the loss of orexin-producing neurons in the brain. orexin agonists are designed to address this underlying orexin deficiency.
TAK Ratings Summary
TAK Quant Ranking